Literature DB >> 19887782

Sustained expression of GRAIL during hematopoiesis results in dysregulated differentiation.

Debra A MacKenzie1, Christine M Seroogy.   

Abstract

BACKGROUND/AIMS: Despite a sophisticated understanding of the hematopoietic developmental program at the transcriptional level, our understanding of the role of E3 ubiquitin ligases remains underdeveloped. The E3 ubiquitin ligase, GRAIL (RNF128), is expressed in the bone marrow, but its role is as yet undefined. In this study, we evaluate the effect of GRAIL expression during hematopoietic differentiation in vitro and in vivo.
METHODS: Retroviral transduction of hematopoietic multipotent progenitor cells was used for methylcellulose colony assays and bone marrow reconstitution.
RESULTS: Enforced expression of GRAIL in colony assays demonstrated skewing of hematopoietic lineage development toward granulocytic/monocytic cells. Bone marrow reconstitution experiments with progenitor cells expressing biologically varied levels of GRAIL demonstrated diminished erythropoiesis and megakaryopoiesis if GRAIL (endogenous or forced) is maintained throughout hematopoiesis.
CONCLUSION: These data highlight a role for GRAIL during hematopoiesis and emphasize the importance of studying posttranslational effects to complement our current understanding of the transcriptional regulation of hematopoiesis. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19887782     DOI: 10.1159/000253591

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  2 in total

Review 1.  GRAIL: a unique mediator of CD4 T-lymphocyte unresponsiveness.

Authors:  Chan C Whiting; Leon L Su; Jack T Lin; C Garrison Fathman
Journal:  FEBS J       Date:  2010-11-16       Impact factor: 5.542

2.  Grail as a molecular determinant for the functions of the tumor suppressor p53 in tumorigenesis.

Authors:  Y-C Chen; J Y-H Chan; Y-L Chiu; S-T Liu; G Lozano; S-L Wang; C-L Ho; S-M Huang
Journal:  Cell Death Differ       Date:  2013-02-01       Impact factor: 15.828

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.